Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

NCT03495960 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: Rituximab
DRUG: Methotrexate
DRUG: Procarbazine
DRUG: Lenalidomide
RADIATION: Radiotherapy
DRUG: Temozolomide

Sponsor

International Extranodal Lymphoma Study Group (IELSG)